The developed anti-cyclin-D1-Cur-PMs (SinaCurcumin®) were evaluated for the physicochemical properties, biopharmaceutical properties and therapeutic efficacy against the BC cells (MCF-7) [143]. The gene discussed is CCND1; the disease is breast cancer.